Mucosal and systemic adjuvant effects of cholera toxin and Cry1Ac protoxin on the specific antibody response to HIV-1 C4/V3 peptides are different and depend on the antigen co-administered

Viral Immunology

Volumn 18, Issue 4, 2005, Pages 695-708

  Esquivel Perez, Rita ^a   Moreno Fierros, Leticia ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; C4 PEPTIDE; CHOLERA TOXIN; CRY1AC PROTOXIN; CYSTEINE; ISOLEUCINE; PROTOXIN; UNCLASSIFIED DRUG; V3 PEPTIDE; VIRUS PROTEIN;

ADJUVANT THERAPY; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INTESTINE MUCOSA; MOUSE; MUCOSA; NONHUMAN; PROTEIN MODIFICATION; RESPIRATORY TRACT MUCOSA; SERUM; VAGINA MUCOSA;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CHOLERA TOXIN; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYSIN PROTEINS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RESPIRATORY MUCOSA; VAGINA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 29844442164     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2005.18.695     Document Type: Article

References (57)

1. Belyakov, L.M., and J.A. Berzofsky. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20:247-253.
2. BenMohamed, L., S.L. Wechsler, and A.B. Nesburn. 2002. Lipopeptide vaccines, yesterday, today, and tomorrow. Lancet Infect. Dis. 2:425-431.
3. Berstad, A.K., J. Holst, B. Mogster, I.L. Haugen, and B. Haneberg. 1997. A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine 15:1473-1478.
4. Berzofsky, J.A. 1991. Development of artificial vaccines against HIV using defined epitopes. FASEB J. 5:2412-2418.
5. Berzofsky, J.A., C.D. Pendleton, M. Clerici, J. Ahlers, D.R. Lucey, S.D. Putney, and G.M. Shearer. 1991. Construction of peptides encompassing mul-tideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88:876-884.
6. Borras-Cuest, F., Y. Fedon, and A. Pellit-Camordan. 1988. Enhancement of peptide immunogenicity by linear polymerization. Eur. J. Immunol. 18:199-202.
7. Bradney, C.P., G.D. Sempowski, H.X. Liao, B.F. Haynes, and H.F. Staats. 2002. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 76:517-524.
8. Castagliulo, I.M., M. Sardina, P. Brun, C. DeRos, C. Mastrotto, L. Lovato, and G. Palu. 2004. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect. Immun. 72:2827-2836.
9. Chen, Y.H., Y. Tianwei, Y. Bai, and M.P. Dierich. 1999. Immunogenicity of the GPGRAFY epitope on synthetic peptides. Immunol. Lett. 69:353-354.
10. Chen, Y.H., Y. Xiao, T.Yu, and M.P. Dierich. 1999. Epitope vaccine: a new strategy against HIV-1. Immunol. Today 20:588-589.
11. Cruz, L.J., E. Iglesias, J.C. Aguilar, L.J. Gonzalez, O. Reyes, F. Albericio, and D. Andreu. 2004. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug. Chem. 15:112-120.
12. Cruz, L.J., E. Iglesias, J.C. Aguilar, D. Quintana, H.E. Garay, C. Duarte, and O. Reyes. 2001. Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. I. Pept. Sci. 7:511-518.
13. Czerkinsky, C., F. Anjuere, J.R. McGhee, A. George-Chandy, J. Holmgren, M.P. Kieny, K. Fujiyashi, J.F. Mestecky, V. Pierrefite-Carle, C. Rask, and J.B. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197-222.
14. Decroix, N., P. Pamonsinlapatham, C.P. Quan, and J.P. Bouvet. 2003. Impairment by mucosal adjuvants and cross-reactivity with variant peptides of the mucosal immunity induced by injection of the fusion peptide PADRE-ELD-KWA. Clin. Diagn. Lab. Immunol. 10:1103-1108.
15. Defoort, J.P., B. Nardelli, W. Huang, and J.P. Tam. 1992. A rational design of synthetic peptide vaccine with a built-in adjuvant. A modular approach for unambiguity. Int. J. Pept. Protein Res. 40:214-221.
16. Fujihashi, K., T. Koga, F.W. van Ginkel, Y. Hagiwara, and J.R. McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants [Review]. Vaccine 7;20:2431-2438.
17. Ge, A.Z., R.M. Pfister, and D.H. Dean. 1990. Hyperexpression of Bacillus thuringiensis delta-endotoxin-encoding gene in Escherichia coli: properties of the product. Gene 93:49-54.
18. Gregoriadis, G. 1994. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods 4:210-216.
19. Hart, M.K, T.J. Palker, T.J. Matthews, A.J. Langlois, N.W. Lerche, M.E. Martin, R.M. Scearce, C. McDanal, D.P. Bolognesi, and B.F. Haynes. 1990. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and hightiters of neutralizing antibodies in rhesus monkeys. J. Immunol. 145:2677-2685.
20. Hart, M.K., J.J. Weinhold, R.M. Scearce, E.M. Washburn, C.A. Clark, T.J. Palker, and B.F. Haynes. 1991. Priming of anti-human immunodeficiency virus (HIV) CDS cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 88:9448-9452.
21. Haynes, B.F., J.V. Torres, A.J. Langlois, D.P. Bolognesi, M.B. Gardner, T.J. Palker, R.M. Scearce, D.M. Jones, M.A. Moody, C. McDana, and T.J. Matthews. 1993. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J. Immunol. 1.51:1646-1653.
22. Höfte, H., and H. Whiteley. 1989. Insecticidal crystal proteins of Bacillus thuringiensis. Microbiol. Rev. 53:242-255.
23. Holmgren, J., N. Lycke, and C. Czerkinsky. 1993. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11:1179-1184.
24. Holmgren, J., C. Czerkinsky, C.K. Eriksson, and A. Mharandi. 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21:89-95.
25. Hordnes, K., T. Tynning, T.A. Brown, B. Haneberg, and R. Jonsson. 1997. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15:1244-1251.
26. Javaherian, K., A.J. Langlois, G.J. LaRosa, A.T. Profy, D.P. Bolognesi, W.C. Herlihy, S.D. Putney, and T.J. Matthews. 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 14;250:1590-1593 [Erratum published in Science 1991;251:13].
27. Erratum published in Science 1991;251:13
28. Jones, H.P., L.M. Hodge, K. Fujihashi, H. Kiyono, J.R. McGhee, and J.M. Simecka. 2001. The pulmonary environment promotes Th2 responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J. Immunol. 167:4518-4525.
29. Kozlowski, P.A., and M.R. Neutra. 2003. The role of mucosal immunity in prevention of HIV transmission [Review]. Curr. Mol. Med. 3:217-228.
30. Li, H.L., Z.Q. Liu, J. Ding, and Y.H. Chen. 2002. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1. Immunol. Lett. 84:153-157.
31. Lindner, W., and F.A. Robey. 1987. Automated synthesis and use of N-chloroacetyl-modified peptides for the preparation of synthetic peptide polymers and peptide-protein immunogens. Int. J. Pept. Protein Res. 30:794-800.
32. Lovgren, K., and M. Larsson. 1994. Conjugation of synthetic peptides to carrier iscoms: factors affecting the immunogenicity of the conjugate. J. Immunol. Methods 173:237-243.
33. Lu, Y., Y. Xiao, J. Ding, M. Dierich, and Y.H. Chen. 2000. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1. Int. Arch. Allergy Immunol. 121:80-84.
34. Marinaro, M., H.F. Staats, H. Kiyono, R.J. Jackson, M. Coste, T. Hiroi, and J.R. McGhee. 1995. The adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and cytokines wich support IgE responses. J. Immunol. 155:4621-4629.
35. Moore, J.P., and P.L. Nara. 1991. The role of the V3 loop in HIV infection. AIDS 5:521-533.
36. Moreno-Fierros, L., N. Garcia, R. Gutierrez, R. Lopez-Revilla, and R.I. Vazquez-Padron. 2000. Intranasal, rectal and intraperitoneal immunization with protoxin Cry 1Ac from Bacillus thuringiensis induces compartmentalized serum, intestinal, vaginal and pulmonary immune responses in Balb/c mice. Microbes Infect. 2:885-890.
37. Moreno-Fierros, L., A.A. Resendiz-Albor, and R. Lopez-Revilla. 1999. Different antiamebic antibody isotype patterns in the large and small intestine after local and systemic immunization of mice with glutaraldehyde fixed Entamoeba histolytica trophozoites. Life Sci. 64:1079-1789.
38. Moreno-Fierros, L., E.J. Ruiz-Medina, R. Esquivel, R. Lopez-Revilla, and S. Pina-Cruz. 2003. Intranasal Cry 1Ac protoxin is an effective mucosal and systemic carrier and adjuvant of Streptococcus pneumoniae polysaccharides in mice. Scand. J. Immunol. 57:45-55.
39. Nara, P.L., R.R. Garrity, and J. Goudsmit. 1991. Neutralization of HIV-1: a paradox of humoral properties. FASEB J. 5:2437-2455.
40. Nishino, Y., M. Kameoka, Y. Okada, Q. Zhong, T. Kimura, I. Azuma, and K. Ikuta. 1994. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24. Vaccine 12:485-491.
41. O'Hagan, D.T., and M. Singh. 2003. Microparticles as vaccine adjuvants and delivery systems [Review]. Expert Rev. Vaccines 2:269-283.
42. Okahashi, N., M. Yamamoto, J.L. Vancott, S.N. Chatfiel, M. Roberts, H. Bulethmann, T. Hiroi, H. Kiyono, and J.R. McGhee. 1996. Oral immunization of interleukin-4(IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4_Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect. Immunol. 64:1516-1521.
43. Palker, T.J., M.E. Clark, A.J. Langlois, T.J. Matthews, K.J. Weinhold, R.R. Randall, D.P. Bolognesi, and B.F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to mv-encoded synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 85:1932-1936.
44. Palker, T.J., T.J. Matthews, A. Langlois, M.E. Tanner, M.E. Martin, R.M. Scearce, J.E. Kim, J.A. Berzofsky, D.P. Bolognesi, and B.F. Haynes. 1989. Polyvalent human Immunodeficiency virus synthetic immunogen comprised of envelope gp 120 T helper cell sites and B cell neutralization epitopes. J. Immunol. 142:3612-3619.
45. Porgador, A., H.F. Staats, B. Faiola, E. Gilboa, and T.J. Palker. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:834-841.
46. Rojas-Hernandez, S., M.A. Rodriguez-Monroy, R. Lopez-Revilla, A.A Resendiz-Albor, and L. Moreno-Fierros. 2004. Intranasal co-administration of the Cry 1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect. Immun. 72:4368-4375.
47. Singh, M., X.M. Li, H. Wang, J.P. McGee, T. Zamb, W. Koff, C.Y. Wang, and D.T. O'Hagan. 1998. Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine 16:346-352.
48. Staats, H.F., W.G. Nichols, and T.J. Palker. 1996. Mucosal immunity to HIV-1, systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:462-472.
49. Stevceva, L., and W. Strober. 2004. Mucosal HIV vaccines: where are we now? [Review], Curr. HIV Res. 2:1-10.
50. Tam, J.P. 1988. Synthetic peptide vaccine design: synthetic and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U.S.A 85:5409-5413.
51. Tomalia, D.A., H. Baker, J. Dewald, M. Hall, G. Kallos, and S. Martin. 1985. A new class of polymers: Starburstdendritic macromolecules. Polymer J. 17:117-132.
52. Vázquez-Padrón, R.I., L. Moreno-Fierros, L. Neri-Bazán, G.A. de la Riva, and R. López-Revilla. 1999. Bacillus thuringiensis Cry 1Ac protoxin is a potent systemic and mucosal adjuvant. Scand. J. Immunol. 49:578-584.
53. Volpina, O.M., A.V. Yarov, M.N. Zhmak, M.A. Kuprianova, A.V. Chepurkin, A.S. Toloknov, and V.T. Ivanov. 1996. Synthetic vaccine against foot-and-mouth disease based on a palmitoyl derivative of the VP1 protein 135-159 fragment of the A22 virus strain. Vaccine 14:1375-1380.
54. Williams, N.A., T.R. Hirst, and T.O. Nashar. 1999. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today 20:95-101.
55. Wilson, A.D., A. Robinson, L. Irons, and C.R. Stokes. 1993. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 11:113-118.
56. Xiao, B.G., and H. Link. 1997. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin. Immunol. Immunopathol. 85:119-128.
57. Xu-Amano, J., R.I. Jackson, H.F. Staats, H. Fujihashi, H. Kiyono, P.D. Burrows, C.O. Elson, S. Pillai, and J.R. McGhee. 1993. Helper T cell subsets for IgA responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178:1309-1320.